Global Investigator Databank Expands to Five Pharmaceutical Company Members and Announces New Investigator Website - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
Global Investigator Databank Expands to Five Pharmaceutical Company Members and Announces New Investigator Website

Global Investigator Databank Expands to Five Pharmaceutical Company Members and Announces New Investigator Website

PR Newswire

LONDON, May 27, 2014 /PRNewswire/ --

Novartis, Janssen, Merck (known as MSD outside the United States and Canada), Lilly, and Pfizer have joined together with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank. In addition, investigators can now access the Investigator Databank through the launch of . Through this website, investigators can securely log in, view and add to their information kept on file by the participating pharmaceutical companies or DrugDev.

The Investigator Databank was established to improve the efficiency of industry-sponsored clinical trials and serves as a one-stop repository where key information about investigators and clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records and site profile forms, are housed. Hosted by a third party, DrugDev, the Investigator Databank benefits both investigators and members of industry by increasing awareness of clinical trial opportunities for investigators, and by reducing the administrative burden of identifying clinical trial sites for the pharmaceutical industry.  

With five member companies now on board, the Investigator Databank has grown to include nearly 180,000 investigators. With 50,000 sites and 7,335 studies, the Investigator Databank already includes four times more data than utilised in the 2013 Tufts analyses of clinical trial sites, published in Therapeutic Innovation
& Regulatory Science, and is already bringing benefits to its member companies in identifying qualified investigators for their studies.  

"During the past five years, pharmaceutical companies have been shifting towards a more collaborative culture aligned around a shared goal of making it easier, cheaper, and faster to conduct clinical research" said Jeff Kasher, Vice President and Chief Operating Officer, Global Medical R&D from Eli Lilly. "While many of these cross-pharmaceutical company collaborations have been successful in generating joint positioning papers and standards, examples of cross company-wide cooperation are much less common. We believe in the Investigator Databank philosophy that sharing information allows for better matching of investigators and future protocols, thus providing a benefit to both industry and doctors."

In addition to facilitating cross-company sharing of investigator names, the Investigator Databank is also unique in allowing investigators to view their information held in member's clinical trial management systems. Through, investigators can maintain their own individual and site profile, including the ability to: view data held on them and their site; comment on their study history record with the member companies; and upload training certificates (which are then mutually recognised by the member companies), CVs, and other documents.  

"The global community of clinical trial investigators is a common and highly valued resource upon which the pharmaceutical industry relies. By supporting our investigators, and helping to optimize how they partner with our industry, we can continue to develop new therapies for the patients who need them," commented David Detoro, Associate Vice President, Clinical Operations from Merck.

David Detoro further added, "The new website enables the upload of standard essential documents such as CVs, GCP training certificates, and non-study specific site profile forms into a global repository, so we can also help sustain our investigator base by eliminating some of the repetitive, administrative tasks associated with study feasibility, site qualification, and site start-up."

The Investigator Databank expects to expand further, welcoming new members who wish to support its aims of reducing administrative burden for investigators and increasing visibility of qualified investigators to research sponsors.

Contact: Elisa Cascade,, +1-610-650-1890

SOURCE DrugDev Ltd


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document

Click here